Neulasta Kit
Product Images NDC 55513-192

Product Visual Gallery

This gallery contains 73 technical images submitted to the FDA as part of the official labeling for Neulasta (NDC 55513-192). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Amgen, Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure (Neulasta 01)

Illustration of a Neulasta prefilled syringe for subcutaneous injection, highlighting labeled parts including the plunger rod, label and expiration date area, syringe barrel containing medicine, and the gray needle cap.*

FDA Label Image

Figure (Neulasta 02)

An instructional diagram showing a drug delivery device with labeled parts including a blue needle cover, automatic needle and cannula opening, adhesive backing, medicine port, pull tabs, cannula window, fill indicator, and status light. The device is designed to administer injection medication.*

FDA Label Image

Figure (Neulasta 03)

An instructional illustration showing two recommended subcutaneous injection sites for Neulasta (pegfilgrastim) injection. The sites highlighted are the back of the upper arm (triceps area) and the abdomen, presented on front and back views of a human figure.*

FDA Label Image

Figure (Neulasta 04)

An instructional illustration showing a Neulasta Onpro on-body injector device designed for subcutaneous injection of pegfilgrastim. The device is depicted alongside its adhesive bandage, highlighting its application for automatic drug delivery. No dosing or label text is visible.*

FDA Label Image

Figure (Neulasta 05)

An exploded diagram of a Neulasta (pegfilgrastim) injection syringe showing labeled parts: plunger rod, label with expiration date, syringe barrel containing medicine, and gray needle cap. The illustration highlights key components of the subcutaneous injection device.*

FDA Label Image

Figure (Neulasta 06)

An instructional illustration showing a hand holding a Neulasta injection syringe. The image focuses on the syringe barrel and needle, highlighting the proper grip and needle orientation for subcutaneous injection administration.*

FDA Label Image

Figure (Neulasta 07)

An instructional illustration showing the insertion of a syringe needle into the medicine port of a prefilled injection device. One hand stabilizes the device while the other hand holds the syringe vertically at a 90-degree angle to administer the injection. The medicine port is labeled in red.*

FDA Label Image

Figure (Neulasta 08)

An instructional illustration showing a hand holding a syringe or injector, accompanied by a graphic of an activation light labeled 'ACTIVATION LIGHT' that is emitting light and the word 'BEEPS', indicating an audio-visual signal likely related to activation or readiness of the device.*

FDA Label Image

Figure (Neulasta 09)

An illustration showing a view of a Neulasta injection device with a focus on its liquid level indicator window. The zoomed inset highlights the indicator with labels for 'FULL' and 'EMPTY' levels, and a red arrow points to the window on the device, signaling how to check if the liquid medicine is full or empty.*

FDA Label Image

Figure (Neulasta 10)

An instructional illustration showing a hand operating the blue activation button on a Neulasta single-use autoinjector device, designed for subcutaneous injection. Adjacent to this, an orange capsule icon labeled FLASHING indicates the device's activation status display.*

FDA Label Image

Figure (Neulasta 11)

Instructional illustration showing use of an automatic needle device for injection. It depicts hands holding the device with a focus on the automatic needle area and a flashing indicator light, likely part of an injection process for a subcutaneous drug such as Neulasta (pegfilgrastim).*

FDA Label Image

Figure (Neulasta 12)

An instructional illustration showing a hand holding a Neulasta on-body injector device. The images demonstrate how to grip and press the device onto the skin for subcutaneous injection.*

FDA Label Image

Figure (Neulasta 13)

An instructional illustration showing the proper placement and administration of a Neulasta (pegfilgrastim) injection using an injector device on the upper arm, indicating subcutaneous injection technique.*

FDA Label Image

Figure (Neulasta 14)

Illustration showing a subcutaneous injection device applied to the abdomen with a person's fingers pressing a button on the device. This likely demonstrates the use or activation of a drug delivery device for Neulasta (pegfilgrastim) injection.*

FDA Label Image

Figure (Neulasta 15)

FDA Label Image

Figure (Neulasta 16)

An instructional diagram illustrating a sequence involving an activation light turning on, followed by a 'BEEPS' sound, cannula insertion, another 'BEEPS' sound, and finally an okay light illumination. The diagram uses colored text boxes and arrows to indicate the process flow.*

FDA Label Image

Figure (Neulasta 17)

FDA Label Image

Figure (Neulasta 18)

An instructional illustration showing incorrect application of the Neulasta injection device adhesive. The left side shows a wrinkled adhesive near the cannula window marked with a red X, and the right side shows a folded adhesive also marked with a red X, highlighting improper adhesive positioning on the device.*

FDA Label Image

Figure (Neulasta 19)

An instructional illustration showing a medical device with an error indication. The device has a red light symbolizing an error, alongside a label saying 'ERROR LIGHT' and the word 'BEEPING' in a spiked speech bubble, indicating an alarm or alert state.*

FDA Label Image

Figure (Neulasta 20)

An instructional diagram showing two views of an on-body injector device for Neulasta (pegfilgrastim). The left side illustrates saturated adhesive on the device, and the right side depicts dripping fluid from the on-body injector, highlighting key functional areas during use.*

FDA Label Image

Figure (Neulasta 21)

FDA Label Image

Figure (Neulasta 22)

An instructional diagram showing a handheld injection device for subcutaneous administration. The device features a small display screen and a sun icon, likely indicating timing or dosage instructions relevant to Neulasta (pegfilgrastim) injection use.*

FDA Label Image

Figure (Neulasta 23)

An instructional illustration showing a device display with a progress indicator bar filled and a green light above it. The device is likely related to the administration or activation of the Neulasta injection (pegfilgrastim) for subcutaneous use, produced by Amgen, Inc.*

FDA Label Image

Figure (Neulasta 24)

FDA Label Image

Figure (Neulasta 25)

FDA Label Image

Figure (Neulasta 26)

FDA Label Image

Figure (Neulasta 27)

An instructional illustration showing a syringe with a needle, demonstrating proper use or administration technique, possibly related to subcutaneous injection for pegfilgrastim (Neulasta). The image includes arrows indicating motion or direction of use.*

FDA Label Image

Figure (Neulasta 28)

FDA Label Image

Figure (Neulasta 29)

FDA Label Image

Figure (Neulasta 30)

FDA Label Image

Figure (Neulasta 31)

Neulasta 4 mg/.4 mL injection label showing a boxed area with the lot number (LOT) field. Labeler is Amgen, Inc. The label is intended for the subcutaneous injection of pegfilgrastim.*

FDA Label Image

Figure (Neulasta 32)

FDA Label Image

Figure (Neulasta 33)

FDA Label Image

Figure (Neulasta 34)

FDA Label Image

Figure (Neulasta 35)

FDA Label Image

Figure (Neulasta 36)

FDA Label Image

Figure (Neulasta 37)

FDA Label Image

Figure (Neulasta 38)

An illustration depicting a syringe, shown vertically with the needle pointed downward. The syringe appears to be pre-filled and is designed for subcutaneous injection, consistent with typical medical injection devices.*

FDA Label Image

Figure (Neulasta 39)

FDA Label Image

Figure (Neulasta 40)

An instructional illustration showing a syringe before and after use. The syringe features labeled parts including the plunger rod, finger grip, label and expiration date, blue safety guard, syringe barrel, medicine, and a gray needle cap. After use, the plunger rod is shown used, the blue safety guard is extended, and the gray needle cap is removed.*

FDA Label Image

Figure (Neulasta 41)

An instructional illustration showing a hand holding a Neulasta prefilled syringe with a blue safety guard. Red arrows indicate where to grab the blue safety guard for proper handling before injection of the pegfilgrastim subcutaneous injection.*

FDA Label Image

Figure (Neulasta 42)

An instructional diagram of a prefilled syringe labeled with parts identified, including the label and expiration date area, the medicine inside the syringe, and the gray needle cap. The syringe is designed for injection use.*

FDA Label Image

Figure (Neulasta 43)

An instructional illustration showing materials used for an injection, including a syringe pre-filled with medication, alcohol prep pads, cotton balls, an adhesive bandage, and a red biohazard sharps disposal container. This setup is typical for subcutaneous injection procedures.*

FDA Label Image

Figure (Neulasta 44)

An instructional anatomical diagram showing preferred subcutaneous injection sites for Neulasta (pegfilgrastim). Highlighted locations include the upper arms, stomach area (abdomen), thighs, and buttocks on front and back views of a human figure.*

FDA Label Image

Figure (Neulasta 45)

An instructional illustration showing the removal of a syringe cap and the disposal of the syringe into a biohazard sharps container, indicating proper handling and disposal of the Neulasta injection syringe.*

FDA Label Image

Figure (Neulasta 46)

An illustration demonstrating the proper technique for administering a subcutaneous injection in the abdominal area, showing hands pinching the skin to create a fold for injection.*

FDA Label Image

Figure (Neulasta 47)

An instructional illustration showing a hand holding a syringe that is being inserted subcutaneously into the skin at a 90-degree angle. The diagram includes a smaller inset showing a 45-degree angle reference for injection technique.*

FDA Label Image

Figure (Neulasta 48)

An instructional illustration showing a hand administering a subcutaneous injection using a prefilled syringe into the skin of a patient's thigh or abdomen. The syringe is held perpendicular to the skin with an arrow indicating the direction to insert the needle.*

FDA Label Image

Figure (Neulasta 49)

FDA Label Image

Figure (Neulasta 50)

Illustration showing hands holding a Neulasta prefilled injection device. A red arrow labeled 'Grab Here' indicates the part of the device to hold while an upward arrow shows the direction to pull for opening or activating the injection device.*

FDA Label Image

Figure (Neulasta 51)

An instructional illustration showing a hand holding a syringe above a red biohazard sharps disposal container with the lid open. An arrow indicates the syringe is to be placed into the container, depicting safe disposal of injection materials.*

FDA Label Image

Figure (Neulasta 52)

Neulasta (pegfilgrastim) injection in a single-use prefilled autoinjector device. The image shows the back view of the autoinjector with a visible yellow indicator in a small rectangular window marked with 'FULL' and 'EMPTY' labels, indicating the injection status. The device is labeled by Amgen, Inc.*

FDA Label Image

Figure (Neulasta 53)

An instructional diagram showing the status light and a fluid level indicator labeled FULL and EMPTY on a device, likely related to the administration of Neulasta (pegfilgrastim) injection. The status light is depicted glowing green, indicating operational status.*

FDA Label Image

Figure (Neulasta 54)

FDA Label Image

Figure (Neulasta 55)

FDA Label Image

Figure (Neulasta 56)

FDA Label Image

Figure (Neulasta 57)

An instructional illustration showing the fill indicator of a syringe or injector device. It compares two states: an empty fill indicator and a full fill indicator, marked accordingly to guide the user on the injection device's liquid level.*

FDA Label Image

Figure (Neulasta 58)

An instructional illustration showing a 27-hour countdown timer and an 'OKAY LIGHT' indicator next to an injection device with a glowing green light and a blue status switch marked 'FULL' and 'EMPTY.' This likely depicts status indicators on a Neulasta injection device.*

FDA Label Image

Figure (Neulasta 59)

An illustration showing a Neulasta Onpro on-body injector attached to the upper arm. The device has a digital display with readable text and a green light indicator, demonstrating application on the skin for subcutaneous injection.*

FDA Label Image

Figure (Neulasta 60)

Illustration showing a Neulasta on-body injector device with an illuminated green OKAY light indicating proper function and a segmented blue indicator marked FULL and EMPTY. The image also includes a timer graphic showing 45 minutes, suggesting a timing or status check related to the injection process.*

FDA Label Image

Figure (Neulasta 61)

FDA Label Image

Figure (Neulasta 62)

An instructional diagram showing incorrect conditions for using the Neulasta on-body injector. The left image depicts a noticeably wet adhesive base, marked incorrect. The right image shows dripping fluid from the on-body injector, also marked incorrect. Both are visual warnings against improper device conditions.*

FDA Label Image

Figure (Neulasta 63)

An illustration showing a medical injection device with a visible fluid window indicating 'FULL' and 'EMPTY' status. The device is accompanied by an illuminated green button labeled 'FINISH LIGHT.' The image includes a green checkmark and the word 'Correct,' suggesting proper use or status of the device.*

FDA Label Image

Figure (Neulasta 64)

An instructional illustration showing an incorrect status indicator for a Neulasta injection device. The image highlights a red error light labeled "ERROR LIGHT" and a graphic text "BEEPING," indicating an error condition on the device's dose indicator window, which is marked between "FULL" and "EMPTY." The sun icon suggests the device should not be exposed to light in this state.*

FDA Label Image

Figure (Neulasta 65)

An instructional illustration depicting a hand holding a Neulasta (pegfilgrastim) injection device against a person's abdomen, showing proper placement for a subcutaneous injection. The device includes a visible indicator window labeled 'FULL' and 'EMPTY' to show the injection status.*

FDA Label Image

Figure (Neulasta 66)

FDA Label Image

Figure (Neulasta 67)

An instructional illustration showing a hand holding a Neulasta injection device. The focus is on the device's window indicator, with a magnified view highlighting the fluid level markings labeled FULL and EMPTY, demonstrating how to interpret when the device is full or empty.*

FDA Label Image

Figure (Neulasta 68)

An instructional illustration showing a hand placing a Neulasta injection device into a red disposal container, demonstrating the proper disposal method for the subcutaneous injection pen after use.*

FDA Label Image

Figure (Neulasta 69)

An illustration showing the correct position of a medical device, likely an injection device, with a visible indicator gauge. The gauge shows levels marked 'FULL' and 'EMPTY,' with the indicator positioned near the 'FULL' side, suggesting the device is properly loaded or filled.*

FDA Label Image

Figure (Neulasta 70)

An illustration showing a vertical indicator with two labels: FULL at the top and EMPTY at the bottom, with a colored bar between them indicating a level closer to FULL. An arrow points to the indicator on the right side.*

FDA Label Image

Figure (Neulasta 71)

An instructional illustration showing an injection device with a red error light indicator and the word "BEEPING" to indicate an incorrect status. The diagram includes a depiction of a container with a full and empty marker and a red X indicating improper use or an error condition.*

FDA Label Image

Principal Display Panel (Kit Carton)

Neulasta Onpro kit (pegfilgrastim) injection 6 mg/0.6 mL in prefilled syringe for subcutaneous use. The label indicates the kit includes a sterile on-body injector and a prefilled syringe for Neulasta. Manufactured by Amgen, Inc, the product contains pegfilgrastim, a pegylated recombinant human granulocyte colony-stimulating factor derived from E. coli, in a preservative-free solution. Storage instructions and usage cautions are provided on the label.*

FDA Label Image

Principal Display Panel Ndc 55513-190-01 1 (0.6 mL Single Dose Prefilled Syringe AMGEN® Neulasta ® (pegfilgrastim) injection Pegylated Recombinant Methionyl Human Granulocyte Colony-Stimulating Factor (PEG-r-metHuG-CSF) derived from E Coli 6 mg 6 mg in 0.6 mL Single Dose Prefilled Syringe For Subcutaneous Use Only This Product Contains Dry Natural Rubber Sterile Solution – No Preservative Rx Only Manufactured by Amgen Inc. Thousand Oaks, CA 91320-1799 U.S.A. U.S. License No. 1080)

Neulasta 6 mg injection in a 0.6 mL single-dose prefilled syringe label. The label indicates the product contains pegfilgrastim, a pegylated recombinant human granulocyte colony-stimulating factor (PEG-r-metHuG-CSF) derived from E. coli. It is for subcutaneous use only, contains dry natural rubber, and is a sterile solution with no preservative. The labeler is Amgen, Inc.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.